245 related articles for article (PubMed ID: 19530745)
21. Statin-associated lower urinary tract symptoms: data mining of the public version of the FDA adverse event reporting system, FAERS.
Fujimoto M; Hosomi K; Takada M
Int J Clin Pharmacol Ther; 2014 Apr; 52(4):259-66. PubMed ID: 24472404
[TBL] [Abstract][Full Text] [Related]
22. PCSK9 Inhibitors and Neurocognitive Adverse Drug Reactions: Analysis of Individual Case Safety Reports from the Eudravigilance Database.
di Mauro G; Zinzi A; Scavone C; Mascolo A; Gaio M; Sportiello L; Ferrajolo C; Rafaniello C; Rossi F; Capuano A
Drug Saf; 2021 Mar; 44(3):337-349. PubMed ID: 33351170
[TBL] [Abstract][Full Text] [Related]
23. Do lipid-lowering drugs cause erectile dysfunction? A systematic review.
Rizvi K; Hampson JP; Harvey JN
Fam Pract; 2002 Feb; 19(1):95-8. PubMed ID: 11818357
[TBL] [Abstract][Full Text] [Related]
24. Assessment of ADRs associated with lipid-lowering agents recorded in the Department of Internal Medicine, University Hospital, Jena.
Hippius M; Farker K; Helble S; Hoffmann A
Int J Clin Pharmacol Ther; 2002 Mar; 40(3):97-101. PubMed ID: 11911604
[TBL] [Abstract][Full Text] [Related]
25. Effect of statins on blood pressure: Analysis on adverse events released by FDA.
You T; Liu XG; Hou XD; Wang XK; Xie HH; Ding F; Yi K; Zhang P; Xie XD
Clin Exp Hypertens; 2017; 39(4):325-329. PubMed ID: 28513233
[TBL] [Abstract][Full Text] [Related]
26. Statin use and incident erectile dysfunction--A nationwide propensity-matched cohort study in Taiwan.
Chou CY; Yang YF; Chou YJ; Hu HY; Huang N
Int J Cardiol; 2016 Jan; 202():883-8. PubMed ID: 26476986
[TBL] [Abstract][Full Text] [Related]
27. Safety profile of antiviral medications: a pharmacovigilance study using the Italian spontaneous-reporting database.
Pugi A; Bonaiuti R; Maggini V; Moschini M; Tuccori M; Leone R; Rossi M; Motola D; Piccinni C; Ferrazin F; Sottosanti L; Mugelli A; Vannacci A; Lapi F
Am J Health Syst Pharm; 2013 Jun; 70(12):1039-46. PubMed ID: 23719881
[TBL] [Abstract][Full Text] [Related]
28. Adverse drug reactions of statins in children and adolescents: a descriptive analysis from VigiBase, the WHO global database of individual case safety reports.
Conte C; Rousseau V; Vert C; Montastruc F; Montastruc JL; Durrieu G; Olivier P
Fundam Clin Pharmacol; 2020 Aug; 34(4):518-520. PubMed ID: 32022302
[TBL] [Abstract][Full Text] [Related]
29. Drug-induced anaphylaxis : case/non-case study based on an italian pharmacovigilance database.
Leone R; Conforti A; Venegoni M; Motola D; Moretti U; Meneghelli I; Cocci A; Sangiorgi Cellini G; Scotto S; Montanaro N; Velo G
Drug Saf; 2005; 28(6):547-56. PubMed ID: 15924506
[TBL] [Abstract][Full Text] [Related]
30. Analysis of National Pharmacovigilance Data Associated with Statin Use in Korea.
Kim H; Kim N; Lee DH; Kim HS
Basic Clin Pharmacol Toxicol; 2017 Nov; 121(5):409-413. PubMed ID: 28500776
[TBL] [Abstract][Full Text] [Related]
31. Media attention and the influence on the reporting odds ratio in disproportionality analysis: an example of patient reporting of statins.
van Hunsel F; van Puijenbroek E; de Jong-van den Berg L; van Grootheest K
Pharmacoepidemiol Drug Saf; 2010 Jan; 19(1):26-32. PubMed ID: 19953500
[TBL] [Abstract][Full Text] [Related]
32. Are lipid-lowering drugs associated with a risk of cataract? A pharmacovigilance study.
Despas F; Rousseau V; Lafaurie M; De Canecaude C; Durrieu G; Bagheri H; Montastruc F; Montastruc JL
Fundam Clin Pharmacol; 2019 Dec; 33(6):695-702. PubMed ID: 31251421
[TBL] [Abstract][Full Text] [Related]
33. Statin-associated immune-mediated necrotizing myopathy: a retrospective analysis of individual case safety reports from VigiBase.
Essers D; Schäublin M; Kullak-Ublick GA; Weiler S
Eur J Clin Pharmacol; 2019 Mar; 75(3):409-416. PubMed ID: 30430215
[TBL] [Abstract][Full Text] [Related]
34. Influence of regulatory measures on the rate of spontaneous adverse drug reaction reporting in Italy.
Motola D; Vargiu A; Leone R; Conforti A; Moretti U; Vaccheri A; Velo G; Montanaro N
Drug Saf; 2008; 31(7):609-16. PubMed ID: 18558794
[TBL] [Abstract][Full Text] [Related]
35. Was the thrombotic risk of rofecoxib predictable from the French Pharmacovigilance Database before 30 September 2004?
Sommet A; Grolleau S; Bagheri H; Lapeyre-Mestre M; Montastruc JL;
Eur J Clin Pharmacol; 2008 Aug; 64(8):829-34. PubMed ID: 18509626
[TBL] [Abstract][Full Text] [Related]
36. Statin-associated gynecomastia: evidence coming from the Italian spontaneous ADR reporting database and literature.
Roberto G; Biagi C; Montanaro N; Koci A; Moretti U; Motola D
Eur J Clin Pharmacol; 2012 Jun; 68(6):1007-11. PubMed ID: 22286160
[TBL] [Abstract][Full Text] [Related]
37. Adverse drug reaction reporting: how can drug consumption information add to analyses using spontaneous reports?
Svendsen K; Halvorsen KH; Vorren S; Samdal H; Garcia B
Eur J Clin Pharmacol; 2018 Apr; 74(4):497-504. PubMed ID: 29255992
[TBL] [Abstract][Full Text] [Related]
38. Statins, neuromuscular degenerative disease and an amyotrophic lateral sclerosis-like syndrome: an analysis of individual case safety reports from vigibase.
Edwards IR; Star K; Kiuru A
Drug Saf; 2007; 30(6):515-25. PubMed ID: 17536877
[TBL] [Abstract][Full Text] [Related]
39. Drug-induced retroperitoneal fibrosis: a case/non-case study in the French PharmacoVigilance Database.
Brasselet D; Chouchana L; Vial T; Damin-Pernik M; Lebrun-Vignes B
Expert Opin Drug Saf; 2020 Jul; 19(7):903-914. PubMed ID: 32374194
[TBL] [Abstract][Full Text] [Related]
40. Pancreatitis associated with the use of GLP-1 analogs and DPP-4 inhibitors: a case/non-case study from the French Pharmacovigilance Database.
Faillie JL; Babai S; Crépin S; Bres V; Laroche ML; Le Louet H; Petit P; Montastruc JL; Hillaire-Buys D;
Acta Diabetol; 2014; 51(3):491-7. PubMed ID: 24352344
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
